Shares of Hoth Therapeutics, Inc. (NASDAQ: HOTH) skyrockets 78.19% to $3.35. The exhilarating rally follows the company’s revelation of extraordinary preclinical results for their experimental Alzheimer’s disease treatment, HT-ALZ.
Hoth Therapeutics revealed that HT-ALZ, a therapeutic currently under development for Alzheimer’s disease, has achieved positive preclinical outcomes that surpassed their previous study findings. In a spatial memory test conducted at Washington University in St. Louis, the higher dosage of HT-ALZ was identified as the most beneficial.
Moreover, the company confirmed that it has successfully completed behavior tests for various parameters such as Locomotor Activity/Exploratory Behavior, Elevated Plus Maze, Spatial Navigation Water Maze, Prepulse Inhibition of Startle, and Conditioned Fear. Hoth Therapeutics is eagerly anticipating the release of further data as it becomes available.
Robb Knie, the CEO of Hoth Therapeutics, stated, “We will now commence the analysis of the animal subjects’ brains to evaluate total plaque load and soluble/insoluble beta-amyloid levels.”
Formerly, Hoth Therapeutics had released preliminary study findings focusing on the impact of orally administered HT-ALZ in reducing the concentration of Aβ (amyloid-beta) in the brain’s interstitial fluid. These studies utilized a well-established mouse model of Alzheimer’s disease (aged APP/PS1+/- mice).
The initial data from these studies demonstrated a notable decrease in Aβ levels in both male and female APP/PS1+/- mice following acute treatment with HT-ALZ. This reduction was observed in comparison to placebo-treated animals and baseline Aβ levels.
Earlier this year, Hoth Therapeutics shared proof-of-concept data generated through cognitive and behavioral assessments conducted on an Alzheimer’s disease mouse model. The findings strongly support the therapeutic cognitive potential of HT-ALZ following chronic oral dosing of 20mg/kg and 40mg/kg of the medication.